Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm just hard pressed to see us meeting and holding $4 without some just ridiculously spectacular unexpected announcement. You're talking about an 700% gain from here based on what? Sure there's some positive news coming, but the time frame between news with OXIS is so large I don't see it keeping it up. I mean we've lost 85% of its value since the R/S.
It's just my opinion. Not trying to bash the stock or spread false info, just sharing my thoughts. On the flip side i would be ecstatic to see some updates posted and watch this thing fly...although its not looking like today is going to be that day haha
Just curious to know what you think is going to push this back up 700% and hold it?
I guess we can just go ahead and assume another R/S is coming
This will be sub .5 if they do not post some sort of news in the next few days. I tried to jump ship yesterday and got greedy and set my sell at .81 instead of .8.
Here's the copy paste of the text, it shows the powerpoint and 3 updated charts as well. It is missing two or three PR's. You and Gibba have commented you can't see it, how that's 'everybody' i have no idea.
Oxis is one of the oldest biotech companies in the US, with operations dating back to 1966, and a long history in the antioxidant / anti-inflammatory market.
Oxis specializes in providing kits and reagents for the high-growth cancer and cardiovascular markets, using its strong IP portfolio of over 90 granted or pending U.S. and International patents.
Oxis has a solid, expandable base business in both Research and Clinical Diagnostics products. Over time, Oxis has developed a reputation for superior quality using its services to assist in drug design and development.
Oxis has a well diversified customer base that includes leading research and clinical institutions and stable foreign distributors with years of experience.
Oxis is well positioned to benefit from the need of pharmaceutical and biotechnology companies to outsource assay development due to its current Good Manufacturing Practices (cGMP) and ISO-quality certification. To this goal, Oxis has recently increased its R&D staff in-house and via consulting arrangements.
The Company’s management team and Board of Directors have the necessary experience to take advantage of growth opportuni-ties in therapeutic and nutraceutical marketplaces.
Company Profile
OXIS is a biotech company that develops and commercializes innovative drugs of therapeutic molecules including cannabinoids, which are focused on several cancer indications. Oxis address the clinical shortcomings of existing commercial products in related fields. OXIS has formed relationships with some of the worlds leading cannabinoid researchers and institutions to advance it's technologies.
Oxis International, Inc., through its subsidiary, Oxis Biotech, Inc., discovers, develops, and commercializes therapeutics from its proprietary product platform in various disease areas in the United States. The company is developing drugs for the treatment of cancer and other unmet medical needs. Its lead drug candidates include OXS-2175, a small molecule therapeutic candidate for the treatment of triple-negative breast cancer; and OXS-4235, a small molecule therapeutic candidate to treat multiple myeloma and associated osteolytic lesions. The company was formerly known as DDI Pharmaceuticals, Inc. and changed its name to Oxis International, Inc. in 1994. Oxis International, Inc. was founded in 1965 and is based in Tampa, Florida.
Overview
Treating Non-Hodgkin's lymphoma
OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.
Treating triple-negative breast cancer
Our lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.
Treating multiple myeloma
Our lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.
Company Website
http://oxis.com
Corporate Overview - Presentation
Fall 2015
Click the link: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10968247
News, Press, Articles
June 4, 2015
Company Press Release
Oxis Biotech Files U.S. Patent Application Covering p62/Sequestosome 1 Inhibitors For The Treatment Of Multiple Myeloma And Secondary Osteolytic Lesions
June 3, 2015
Company Press Release
Millennium Healthcare Inc. Appoints Anthony Cataldo, CEO of Oxis Biotech, to Board of Advisors
May 12, 2015
Company Press Release
OXIS Biotech Retains The Emmes Group To Assist With Its Strategic Business And Therapeutic Development Initiatives
May 6, 2015
Company Press Release
Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board
April 14, 2015
Company Press Release
Oxis Biotech Inc. Announces CEO Anthony Cataldo to Participate in Business of Biotech 2015 at the Moffitt Cancer Center
April 1, 2015
Company Press Release
Oxis Biotech Discusses Its Immunotherapeutic Development Strategy
March 31, 2015
Company Press Release
Oxis International Inc. Announces Request for Euronext Trading Suspension
March 30, 2015
Company Press Release
MarijuanaStocks.com to Host Oxis International (OXIS) Conference Call with CEO Tony Cataldo
March 26, 2015
Company Press Release
Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh
March 25, 2015
Company Press Release
Oxis Biotech Inc. Announces Corporate Update Conference Call for March 31
March 12, 2015
Company Press Release
Oxis Biotech Licenses Rights To Antibody-Drug Conjugates For The Treatment Of Cancer
February 24, 2015
Company Press Release
OXIS Biotech Issues Letter to Shareholders
February 10, 2015
Company Press Release
Oxis Biotech Inc. Announces Appointment of Dr. Lisa A. Haile to Scientific Advisory Board
February 4, 2015
Company Press Release
Oxis Biotech Inc. Provides Update for P62-ZZ Multiple Myeloma Patent Application
January 29, 2015
Company Press Release
Oxis International, Inc. (OTCQB: OXIS) Announces Approval for Up-Listing to the OTCQB
OXIS on SeekingAlpha Alongside GW Pharma and Insys Therapeutics
This Is Where The Investment Opportunity Is Right Now In Cannabis
January 15, 2015
Company Press Release
Oxis Biotech Inc. Announces Appointment of Dr. James J Mulé to Scientific Advisory Board
January 12, 2015
Company Press Release
Oxis Biotech Executes Worldwide Exclusive Patent Licensing "P62 Chemical Agents and Multiple Myeloma Therapeutics" with Dr. Xiang-Qun (Sean) Xie, Professor of Pharmaceutical Sciences at University of Pittsburgh
Marijuana Stocks.com Article
If You Could Have Bought $GWPH & $INSY at 0.02 Would You?
November 20, 2014
Company Press Release
OXIS International, Inc. announces Changes in Management Team
November 11, 2014
Company Press Release
OXIS International announces Oxis Biotech Inc., Completion of $2.675 million Financing, Appointment of Chief Financial Officer and Board Member
OXIS Conference Call March 31, 2015
CEO Interview with The Wolf of Weedstreet
Management
ANTHONY J. CATALDO
Chairmen and Chief Executive Officer Oxis International, Inc./Oxis Biotech, Inc.
Mr. Cataldo joined the Oxis International Board of Directors in July of 2014. From February 2011 to June 2013 Mr. Cataldo served as FOUNDER and Chairman/CEO of Genesis Biopharma, inc., now known as Lion Biotechnologies, Inc., (LBIO). Mr. Cataldo created the highly successful Lion/Genesis (LBIO) with the inclusion of assets acquired from the National Cancer Institute for the treatment of stage four melanoma. Mr. Cataldo has extensive experience in the biotechnology sector having served as Chairman/CEO of several biotech companies including: MultiCell Technologies, Inc., Calypte Biomedical Corporation, and Senetek, PLC.
STEVEN WELDON
Chief Financial Officer
Mr. Weldon joined the Oxis International, Inc. team as a member of the Board of Directors in September 2014. He was appointed Chief Financial Officer in November 2014. Mr. Weldon was elected President of Oxis International, Inc. November 19, 2014. Mr. Weldon is a certified public accountant licensed to practice in the state of Florida. Mr. Weldon has over 15 years of financial and accounting experience with public and private companies. He most recently was the CFO of Grow BLOX (GBLX) which has made inroads in the newly expanding CANNABIS related field. Steven received his Bachelor of Science degree and his Masters in Business Administration from Florida Southern College, where he was an adjunct professor. Mr. Weldon has years of experience as board member, Chief Financial Officer and Chief Executive Officer of publicly traded companies.
SCIENTIFIC ADVISORY BOARD
XIANG-QUN (SEAN) XIE, M.D., Ph.D., EMBA
Sean Xie, MD, PhD, EMBA is a tenured Professor at the Department of Pharmaceutical Sciences/Drug Discovery Institute at University of Pittsburgh and Associate Dean for Research Innovation at the School of Pharmacy. He is Principal Investigator of an integrated research laboratory of CompuGroup, BioGroup and ChemGroup, and Founding Director of Computational Chemical Genomics Screening Center. Dr. Xie is also Director/PI of NIH funded National Center of Excellence for Computational Drug Abuse Research. Dr. Xie holds joint faculty positions at the Departments of Computational System Biology and Structural Biology, and Pittsburgh Cancer Institute MT/DD Program. He serves as an invited guest editor for AAPS Journal, Editorial Board of American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology and Toxicology. In 2013, he was named an honorary professor of Chinese Academy of Medical Sciences & Peking Union Medical College. Dr. Xie is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.
JAMES J. MULE, Ph.D.
Dr. James J. Mule, Ph.D. serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center. He then moved to Palo Alto, Calif., where he was involved in the birth of two startup companies while an adjunct faculty member in the Department of Surgery, Stanford University. He moved to Ann Arbor, Mich., as the Director of the Tumor Immunology and Immunotherapy Clinical Research Programat the University of Michigan Comprehensive Cancer Center. Dr. Mule is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. The work in these areas has helped to develop new treatments for advanced cancer patients. Dr. Mule serves on the Advisory Boards of seven NCI-designated Cancer Centers and was a member of the NCI’s Board of Scientific and Clinical Counselors. He serves as Chair of the Cellular, Tissue and Gene Therapy Advisory Committee of CBER, FDA, is a Special Government Employee of the NCI and the FDA. Dr. Mule is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors.
STEPHEN M. CHANG, Ph.D.
Dr. Stephen M. Chang is Vice President-Research & Development at New York Stem Cell Foundation, Chief Scientific Officer at Stemgent, Inc., and Independent Director at MultiCell Technologies, Inc. He is on the Board of Directors at MultiCell Technologies, Inc. Dr. Chang was previously employed as Chief Scientific Officer & Vice President by Canji, Inc., Chief Scientific Officer & Vice President by Schering-Plough Research Institute, and President & Chief Executive Officer by MultiCell Immunotherapeutics, Inc. He also served on the board at Histogen, Inc. He received his undergraduate degree from the University of Michigan and a doctorate degree from the University of California, Irvine.
LISA A. HAILE, Ph.D.
Dr. Haile has special technical experience in molecular biology, immunology, plant biotechnology, including transgenic plants, cell biology, diagnostics, therapeutics, theranostics, virology, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management. Dr. Lisa Haile concentrates on patent protection.
Information on Multiple Myeloma & Cannabidiol (CBD)
After studying the effects of cannabidiol on multiple myeloma cells, researchers found that; “CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF-?B pathways with major effects in TRPV2+ cells.”
They conclude that; “These data provide a rationale for using CBD to increase the activity of proteasome inhibitors in MM.”
The study, which validates a recent National Institute of Health study which also found that cannabidiol can inhibit cancer cells, was conducted by researchers at the School of Pharmacy at the University of Camerino in Italy.
Stock Information:
Authorized Shares - 600,000,000 a/o Jan 21, 2015
Outstanding Shares - 600,000,000 a/o Apr 23, 2015
Float: 500,863,979 a/o Jan 21, 2015
Market Value - $8,880,000 a/o Oct 23, 2015
shows for me
holdin this bag sucks....:/
I chipped in another 1500 shares at .68
they are years out from having a commercially available product, but the chance to make money here in that time frame is positive. Just depends on whether you like to invest or trade.
nothing to sink teeth into. patent is fluff as if that wasn't going to happen, the previous is good news, but its minimal as all hell and 1 patient literally means jack in this area.
I got my buy set up at .99. Gonna average my 1.40's and 1.50's down. I'll put a few k in around that price point then forget about it till next year.
My second round of $1.50 gettin filled. WOop! Could of swore i was told $1.50's were gone haha
i'm holdin out for more 1.50's. Could miss something crazy in the next week or two, but so be it if that's the case.
He doesn't. It very well could be without some sort of PR in the several weeks. 15,700 volume just isn't gonna do it. Interest is finally brewing in AMDA leading up to news and it looks like we're gonna cross 2MM volume today. That's what's needed here.
No Volume.
whole market is bleeding
I posted this because I saw it circling around and it was mentioned here. Whether this is fact or not, I do not know.
My 1.5's filled! Woop! been open for two weeks.
Equity Trader Alert #2016 - 14
Reverse Split and CUSIP Change for Amedica Corporation (AMDA)
Amedica Corporation (AMDA) will effect a one-for-fifteen (1-15) reverse split of its common stock. The reverse split will be effective at the opening of business on Monday, January 25, 2016. In conjunction with the reverse split, the CUSIP number will change to 023435209.
If you would like to register as a market maker in AMDA, contact Nasdaq Trading Operations at +1 212 231 5100
I just disagree is all. good luck
I would think that outside of racing and boats, electric motor technology coupled with solar and battery advances will dominate the majority of those items in the next decade. I don't see a scenario where someone is willing to pay more for a more efficient chainsaw engine.
You mention India, but look into the NEMMP and really just India's policies over the past 5 years. Their 5th 12-year plan has a major cornerstone in strictly electric vehicle production for use by both the government and private sector as a whole, while providing big incentives for purchasing electric vehicles, whether 2, 3, or 4-wheeled. They are investing heavily in solving electrical service issues in several states as well due to that specifically hindering people from wanting to purchase electric vehicles.
China is a lot better market today, since they generate 70%-80% from coal fired plants, so there's really no net loss of pollution in going electric. However, they are dumping money heavily into renewable sources to combat rampant pollution and in 20 years, more than 50% of their electrical capacity will be in renewables, nuclear, and gas. At that point the benefit for electric vehicles will be a lot more prominent.
Generators, heavy equipment engines, maybe a car engine manufacturer for a chinese or indian car brand....those are the areas where I personally see any area for success. Industry will be able to swallow the up front costs for future performance and efficiency a lot better than private individuals will. Just my opinion. It just seems that the snail pace of this company and the introduction of their product into the markets is really going to hurt them as other technologies progress more rapidly.
I have a fairly large chunk of cash invested as well and I've been adding to it for nearly a year. I made some good cash on my "trading" account coming up from the low 20's and selling in the 70's back in the spring/summer.
I'm just saying I've seen the FDA do some odd stuff is all.
just be prepped for that hard drop if they come back with more questions
world markets are teetering close the edge, dow has lost nearly 2,000 points in 30 days, and this week 3 of the worlds largest investment banks basically said "sell everything". Market is not healthy. I put my 401k 90% in guaranteed funds today
im just hoping to get to .2 before R/S so i can sell out and sit out of the market this year
...but this would NEVER go sub-penny:)
it's doing what most all the other bio r/s that I looked at. Good buying opportunity . Unfortunately I don't have the available funds to put anything worthwhile here. Hopefully it holds down for two weeks till i sell out elsewhere:)
that is correct
my etrade wont give me that, odd
i spent awhile yesterday looking through historical charts of biotech r/s and although there are outliers and this could well be an outlier, they generally spike for a few weeks then drop below their r/s pps before they come back up and level out where the market sees fit
If you're planning on holding for years, sure, you could triple your money and I would hope that with the shares you're holding your plan is to just forget about this thing and let time move. I am more curious about the shorter 6 month term
Gibba,
What's your reasoning for believing this will act differently than LBIO after split?
Gibba, did they change that law? It used to be 30 days just a few years ago
What a crazy 20 minutes....
What a crazy 20 minutes....
Super screwy here....
im dumpin on friday if nothing changes between now and then
Keep in mind that Cummins Power Systems is just a distributor. I do a lot of business with Yancey. They've been the sole distributor for Caterpillar for about 100 years in my region. The VP of machine sales and the GM of regional sales are regular contacts of mine. Recently asked them around this topic and the response I got back was that their input might be considered relevant if they pushed hard enough with a new technology, but CAT would absolutely have to be involved for there to be any real back and forth around interest/testing of new technologies. If we aren't seeing names from Cummins and not Cummins Powers Systems names, then they more than likely aren't at any serious point.
I don't see any lies, I just see careful plays with words. I could "Sign a 3-year Supply Agreement with XXXX" just by sending XXXX a purchase order for 10 pieces of equipment a year for three years. I could "Negotiate with XXXX for long-term agreement" just by negotiating for a $100,000 5-year service contract. I have "partnerships" with dozens of companies.
I wish the longs the best, the design and technology looks impressively promising, but I feel that this company is jerking people around. Not pointlessly bad mouthing, this is just my last post here and sharing my thoughts. Good luck!
Agreed, i'm not even going to watch it anymore. Goodluck to all, but in my opinion this is a pretty awesome long term moneypit. If you got the cash to properly day-trade, this is a good moneymaker though.
yawn
it's sleeping